Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Oct 9;5(12):1926-1930.
doi: 10.1002/ccr3.1214. eCollection 2017 Dec.

Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment

Rahul Gosain  1 , Amitoj Gill  1 , Jacob Fuqua  2 , Lesley H Volz  3 , Mika R Kessans Knable  3 , Ryan Bycroft  3 , Sarah Seger  3 , Rohit Gosain  4 , Jorge A Rios  5 , Ju-Hsien Chao  6
Affiliations
Case Reports

Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment

Rahul Gosain et al. Clin Case Rep. .

Abstract

Drug-induced aHUS is rare; however, early diagnosis is vital to reduce morbidity and mortality. With confirmation of the diagnosis, eculizumab appears to be a viable treatment option to suppress the pro-inflammatory surge. Furthermore, adverse side effects of medications such as carfilzomib and gemcitabine should be considered in the appropriate settings.

Keywords: Carfilzomib; eculizumab; gemcitabine; hemolytic–uremic syndrome; thrombotic microangiopathy; thrombotic thrombocytopenia purpura.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient 1 Platelet response to PLEX and eculizumab.
Figure 2
Figure 2
Patient 1 Serum Creatinine response to PLEX and eculizumab.
Figure 3
Figure 3
Patient 2 Platelet response to PLEX and eculizumab.
Figure 4
Figure 4
Patient 2 Serum creatinine response to PLEX and eculizumab.
Figure 5
Figure 5
Treatment algorithm for patients presenting with TMA 14.
See this image and copyright information in PMC

References

    1. Besbas, N. , Karpman D., Landau D., Loirat C., Proesmans W., Remuzzi G., et al. 2006. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 70:423–431. - PubMed
    1. Noris, M. , and Remuzzi G.. 2009. Atypical hemolytic‐uremic syndrome. N. Engl. J. Med. 361:1676–1687. - PubMed
    1. Loirat, C. , and Fremeaux‐Bacchi V.. 2011. Atypical hemolytic uremic syndrome. Orphanet. J. Rare. Dis. 6:60. - PMC - PubMed
    1. Al‐Nouri, Z. L. , Reese J. A., Terrell D. R., Vesely S. K., and George J. N.. 2015. Drug‐induced thrombotic microangiopathy: a systemic review of published reports. Blood 125:616–618. - PMC - PubMed
    1. Ruggenenti, P. , Noris M., and Remuzzi G.. 2001. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 60:831–846. - PubMed

Publication types

LinkOut - more resources